Cytokinetics, Incorporated
|
280 E. Grand Avenue
South San Francisco, CA 94080
United States |
| Tel: |
1/650-624-3000 |
| URL: |
http://www.cytokinetics.com |
|
 |
| Primary Symbols & Exchanges: |
| CYTK - NASDAQ |
|
|
| Primary Industry: |
| Pharmaceutical |
|
|
SIC Industry Code:
|
|
NAICS Industry Code:
|
|
Thomson Financial Business Description:
| The Company's principal activity is to develop small molecule therapeutics for the treatment of cardiovascular diseases and cancer. The Company's drug development pipeline consists of a drug candidate for the treatment of heart failure, being developed in both an intravenous and oral formulation and two drug candidates and a potential drug candidate for the treatment of cancer. The cytoskeleton is a complex that plays a fundamental role within every human cell. It's focuses on the cytoskeleton, which enables it to develop safer and more effective drugs for the treatment of these diseases. The Company has developed a cell biology driven approach and proprietary technologies to evaluate the function of many interacting proteins in the complex environment of the intact human cell. The Company currently has three novel small molecule drug candidates in clinical development and two novel small molecule potential drug candidates currently in preclinical development. |
|
Alacra Alerts:
 
|
Receive alerts on the latest reports on Cytokinetics, Incorporated
Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
|
|
